Papers
2
Total Citations
19
H-Index
2
About
Andrew Fuson is a surgeon-scientist whose research bridges the frontiers of otolaryngology, surgical oncology, and advanced intraoperative imaging. His most cited work, the 2024 interim Phase II study on panitumumab-IRDye800CW during transoral robotic surgery (TORS) for oropharyngeal cancer, has already garnered 15 citations—a remarkable impact for a recent publication. This pioneering investigation addresses a critical challenge in TORS: the loss of tactile feedback during minimally invasive procedures. By employing a fluorescently labeled antibody targeting EGFR, Fuson and his team have developed a method to visualize tumor margins in real time, potentially reducing positive margins and improving functional outcomes for patients with oropharyngeal squamous cell carcinoma. His earlier work explored hypopharyngeal applications of novel flexible robotic systems, demonstrating his sustained commitment to advancing robotic surgical techniques. Fuson’s contributions are particularly significant given the rising incidence of HPV-related oropharyngeal cancers and the need for precision-sparing approaches. His research not only enhances surgical accuracy but also exemplifies how molecular imaging can transform oncologic surgery, offering patients better cancer control with fewer functional deficits.
Research Focus
Key Achievements
Top Papers
- 1
- 2